No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease

Neurobiol Aging. 2009 Aug;30(8):1327-8. doi: 10.1016/j.neurobiolaging.2007.11.006. Epub 2008 Feb 20.

Abstract

This study sought to determine if there are detectible influences on the symptoms of Alzheimer's disease (AD) from the genetic risk factor for AD, the epsilon4 allele of apolipoprotein-E (APOE). Using data from two cohorts of AD patients, a cross-sectional latent variable model of AD was tested with three symptom factors explaining variability in the observed variables after taking a general neurological factor into account. No significant influence of epsilon4 was detected. APOE's effect in AD may occur prior to clinical symptoms, or may simply be more subtle than these instruments can detect.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Alzheimer Disease / genetics*
  • Apolipoprotein E4 / genetics*
  • Cohort Studies
  • Cross-Sectional Studies
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Humans
  • Risk Factors

Substances

  • Apolipoprotein E4